

# Blood transfusion reduction with intravenous iron in gynaecological cancer patients receiving chemotherapy

|  |   |  |
|--|---|--|
| <b>Submission date</b><br>22/09/2009   | <b>Recruitment status</b><br>No longer recruiting | <input type="checkbox"/> Prospectively registered    |
|  |   | <input type="checkbox"/> Protocol                    |
| <b>Registration date</b><br>01/10/2009 | <b>Overall study status</b><br>Completed          | <input type="checkbox"/> Statistical analysis plan   |
|  |   | <input type="checkbox"/> Results                     |
| <b>Last Edited</b><br>12/09/2011       | <b>Condition category</b><br>Cancer               | <input type="checkbox"/> Individual participant data |
|  |   | <input type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Tarinee Manchana

### Contact details

1873 Rama IV, Patumwan  
Bangkok  
Thailand  
10330

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

## Study information

**Scientific Title**

Blood transfusion reduction with intravenous iron in gynaecological cancer patients receiving chemotherapy: a randomised controlled trial

**Study objectives**

Chemotherapy-induced anaemia is common in gynaecological cancer patients. Blood transfusion is the main treatment for this, however it has some serious adverse events. Most of the patients who have had a blood transfusion for chemotherapy-induced anaemia continue to require transfusions in the consecutive cycles.

This randomised controlled trial is aimed at exploring whether intravenous iron could reduce the need for blood transfusions in anaemic gynaecological cancer patients receiving platinum-based chemotherapy.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics Committee of Chulalongkorn University approved on the 28th August 2008 (ref: 237/51)

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Chemotherapy-induced anaemia

**Interventions**

Study group: Iron sucrose 200 mg intravenous drip over 30 minutes as a single dose  
Control group: Ferrous sulphate 200 mg oral three times a day until the next cycle of chemotherapy

Patients will be contacted every week for monitoring of their complete blood count until the next cycle of chemotherapy (3 - 4 weeks depending on the chemotherapy regimen).

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Intravenous iron

**Primary outcome measure**

The incidence of blood transfusion at the consecutive cycle of chemotherapy between oral and intravenous iron, measured at the time of next cycle of chemotherapy (3 - 4 weeks depending on the chemotherapy regimen).

**Secondary outcome measures**

In both groups, assessed at the next cycle of chemotherapy (3 - 4 weeks depended on the chemotherapy regimen):

1. Haemoglobin and haematocrit increment
2. Number of blood transfusion units
3. Adverse events
4. Quality of life (QOL), also measured before treatment

**Overall study start date**

31/08/2008

**Completion date**

31/07/2009

## **Eligibility**

**Key inclusion criteria**

1. Female participants aged 20 - 65 years
2. Normal liver function
3. Normal kidney function
4. No prior radiotherapy or having received radiotherapy
5. At least one remaining cycle of chemotherapy

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

44 patients

**Key exclusion criteria**

1. Iron hypersensitivity
2. Risk of iron overload such as chronic renal failure or thalassaemia major
3. Progressive disease
4. Bone marrow metastasis
5. Inability to monitor weekly complete blood counts

**Date of first enrolment**

31/08/2008

**Date of final enrolment**

31/07/2009

## **Locations**

**Countries of recruitment**

Thailand

**Study participating centre**

1873 Rama IV, Patumwan

Bangkok

Thailand

10330

## **Sponsor information**

**Organisation**

Chulalongkorn University (Thailand)

**Sponsor details**

Faculty of Medicine

Department of Obstetrics and Gynaecology

1873, Rama IV, Patumwan

Bangkok

Thailand

10330

**Sponsor type**

University/education

**Website**

[http://chula.ac.th/chula/th/index\\_king60.html](http://chula.ac.th/chula/th/index_king60.html)

**ROR**

<https://ror.org/028wp3y58>

# Funder(s)

## Funder type

University/education

## Funder Name

Chulalongkorn University (Thailand) - Department of Obstetrics and Gynaecology, Faculty of Medicine

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration